Substrate autoregulation of glucose transport: hexose 6-phosphate mediates the cellular distribution of glucose transporters.
Exposure of rat skeletal muscle and skeletal muscle cell lines to high glucose levels results in a time- and dose-dependent reduction of the rate of hexose uptake, paralleled by a reduction in the plasma membrane density of glucose transporters. The mechanism of this process was investigated in cultured L8 myocytes. Low concentrations (0.5-2.0 mmol/l) of deoxyglucose mimicked the downregulatory action of 20 mmol/l glucose both regarding the time-course and magnitude of the effect, but in an irreversible manner. A dose-dependent relationship between intracellular accumulation of deoxyglucose 6-phosphate and the magnitude of the downregulatory response was observed. Depletion of intracellular deoxyglucose 6-phosphate restored the rate of hexose transport to the control level. The reduction of hexose transport activity by deoxyglucose occurred independently of ATP depletion which by itself produced the opposite effect. The effects of deoxyglucose and high glucose on hexose transport were associated with reduced transport maximal velocity and GLUT1 transporter abundance in the plasma membranes of myocytes, as assessed by cell surface biotinylation. The reduction of myocyte GLUT1 mRNA content, observed after exposure to high glucose, did not accompany the transport down regulatory action of deoxyglucose. We suggest that hexose 6-phosphate is the mediator of the downregulatory signal for subcellular redistribution of GLUT1 in L8 myocytes. The signal responsible for reducing the GLUT1 mRNA level may be related to glucose metabolites downstream of the hexokinase reaction.
Sasson
S
S
Department of Pharmacology, Hebrew University of Jerusalem Faculty of Medicine, School of Pharmacy, Israel.
Kaiser
N
N
Dan-Goor
M
M
Oron
R
R
Koren
S
S
Wertheimer
E
E
Unluhizarci
K
K
Cerasi
E
E
D000255:Adenosine Triphosphate / Q000096:biosynthesis; D000621:Aminoisobutyric Acids / Q000032:analysis / Q000378:metabolism; D000818:Animals; D000963:Antimetabolites / Q000032:analysis / Q000378:metabolism* / Q000494:pharmacology; D015153:Blotting, Western; D002460:Cell Line; D002463:Cell Membrane Permeability / Q000187:drug effects / Q000502:physiology; D003847:Deoxyglucose / Q000032:analysis / Q000378:metabolism* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation / Q000187:drug effects / Q000502:physiology; D051272:Glucose Transporter Type 1; D006593:Hexokinase / Q000378:metabolism; D006600:Hexosephosphates / Q000378:metabolism*; D007106:Immune Sera / Q000276:immunology; D007700:Kinetics; D008565:Membrane Proteins / Q000032:analysis / Q000187:drug effects / Q000502:physiology; D009004:Monosaccharide Transport Proteins / Q000032:analysis / Q000187:drug effects / Q000502:physiology*; D018482:Muscle, Skeletal / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D011817:Rabbits; D051381:Rats; D013997:Time Factors; D014316:Tritium; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology
D000621:Aminoisobutyric Acids; D000963:Antimetabolites; D051272:Glucose Transporter Type 1; D006600:Hexosephosphates; D007106:Immune Sera; D008565:Membrane Proteins; D009004:Monosaccharide Transport Proteins; D012333:RNA, Messenger; C495679:Slc2a1 protein, rat; D014316:Tritium; D000255:Adenosine Triphosphate; D003847:Deoxyglucose; D006593:Hexokinase